entacapone   Click here for help

GtoPdb Ligand ID: 6647

Synonyms: Comtan® | Comtess® | OR-611
Approved drug PDB Ligand
entacapone is an approved drug (FDA (1999), EMA (1998))
Compound class: Synthetic organic
Comment: Entacapone inhibits catechol O-methyltransferase (COMT).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 127.7
Molecular weight 305.1
XLogP 2.43
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCN(C(=O)C(=Cc1cc(O)c(c(c1)[N+](=O)[O-])O)C#N)CC
Isomeric SMILES CCN(C(=O)/C(=C/c1cc(O)c(c(c1)[N+](=O)[O-])O)/C#N)CC
InChI InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+
InChI Key JRURYQJSLYLRLN-BJMVGYQFSA-N
No information available.
Summary of Clinical Use Click here for help
Used to improve the efficiency of levodopa / carbidopa treatment in patients with Parkinson's disease.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
COMT is an enzyme that degrades catecholamines, including levodopa (dopamine precursor) used to treat Parkinson's disease (PD). By inhibiting COMT action, entacapone prolongs the bioavailability of levodopa in combination PD therapy.
External links Click here for help